The presence of various genes encoding for the resistance and virulence factors of Staphylococcus aureus strains isolated from ocular infections_
| Studied genes | Hospitalization (n;%) | Total n = 83 | |
|---|---|---|---|
| Yes, n = 61 (73.4%) | No, n = 22 (26.5%) | ||
| mecA (n = 6; 7%) | 4 (6.5%) | 2 (9.0%) | 6 (7.2%) |
| ermA (n = 13; 16%) | 8 (13.1%) | 5 (22.7%) | 13 (15.6%) |
| mup (n = 4; 5%) | 4 (6,5%) | 0 | 4 (4.8%) |
| lukE (n = 60; 72%) | 45 (73.7%) | 15 (68.1%) | 60 (72.2%) |
| tsst-1 (n = 10; 12%) | 10 (16.3%) | 0 | 10 (12.0%) |
| etA (n = 3; 4%) | 2 (3.2%) | 1 (4.5%) | 3 (3.6%) |
| etB (n = 2; 2%) | 2 (3.2%) | N0 | 2 (2.4%) |
Staphylococcus aureus strains isolated from ocular infections in different patient age groups with consideration of gender, hospitalization, and the results of the CRA test_
| Characteristics of the study group | Hospitalization (n; %) | OR (95% CI) | p-value | ||
|---|---|---|---|---|---|
| Yes, n = 61 (73.4%) | No, n = 22 (26.5%) | Total, N = 83 | |||
| Age (years) by categories [n; %] | |||||
| < = 18 years | 15 (24.5%) | 1 (4.5%) | 16 (19.2%) | 2.5 (0.20–32.99) | 0.027 |
| 19–64 years | 12 (19.6%) | 2 (9.0%) | 14 (16.8%) | 1.00 (ref.) | |
| > = 65 years | 34 (55.7%) | 19 (86.3%) | 53 (63.8%) | 8.4 (1.03–68.49) | |
| Gender [n; %] | |||||
| Female | 26 (42.6%) | 12 (54.5%) | 38 (45.7%) | 0.6 (0.23–1.65) | 0.454 |
| Male | 35 (57.3%) | 10 (45.4%) | 45 (54.2%) | ||
| The positive CRA (Congo Red Agar) biofilm test result (n; %) | |||||
| yes | 45 (73.7%) | 10 (45.4%) | 55 (66.2%) | 3.3 (1.22–9.31) | 0.016 |
| no | 16 (26.2%) | 12 (54.5%) | 28 (33.7%) | ||
Drug resistance of Staphylococcus aureus strains isolated from ocular infections_
| Antimicrobial category | Antimicrobial agent | Hospitalization n (%) | Total, N = 83 | |
|---|---|---|---|---|
| Yes, n = 61 (73.4%) | No, n = 22 (26.5%) | |||
| Aminoglycosides | Gentamicin | 4 (6.5%) | 1 (4.5%) | 5 (6.0%) |
| Amikacin | 5 (8.1%) | 3 (13.6%) | 8 (9.6%) | |
| Tobramycin | 9 (14.7%) | 5 (22.7%) | 14 (16.8%) | |
| Neomycin | 37 (60.6%) | 11 (50.0%) | 48 (57.8%) | |
| Fluoroquinolones | Ciprofloxacin | 4 (6.5%) | 7 (31.8%) | 11 (13.2%) |
| Moxifloxacin | 2 (3.2%) | 4 (18.1%) | 6 (7.2%) | |
| Folate pathway inhibitors | Trimethoprim/sulfamethoxazole | 3 (4.9%) | 2 (9.0%) | 5 (6.0%) |
| Lincosamides | Clindamycin | 13 (21.3%) | 8 (36.3%) | 21 (25.3%) |
| Macrolides | Erythromycin | 13 (21.3%) | 8 (36.3%) | 21 (25.3%) |
| Phenicols | Chloramphenicol | 4 (6.5%) | 1 (4.5%) | 5 (6.0%) |
| Tetracyclines | Tetracycline | 11 (18.0%) | 3 (13.6%) | 14 (16.8%) |
| Non-susceptible to antimicrobial agents in (above) categories | ||||
| fully susceptible (0 categories) | 37 (60.6%) | 6 (27.2%) | 61 (73.4%) | |
| one category | 25 (40.9%) | 4 (18.1%) | 29 (34.9%) | |
| 2 categories | 12 (19.6%) | 6 (27.2%) | 18 (21.6%) | |
| 3 categories | 5 (8.1%) | 1 (4.5%) | 6 (7.2%) | |
| 4 categories | 2 (3.2%) | 1 (4.5%) | 3 (3.6%) | |
| 5 categories or more | 2 (3.2%) | 4 (18.1%) | 5 (6.0%) | |
| MRSA, yes | 3 (4.9%) | 2 (9.0%) | 5 (6.0%) | |
| MLSB, yes | 14 (22.9%) | 8 (36.3%) | 22 (26.5%) | |